P2P Group Increases Biometric Detection Range by 166%--Transforming Security, Defence and Aged Care
Highlights:
Opens new markets in border control, defence, and passive health monitoring
Extends wireless heart rate and breathing detection range from 3m to 8m using standard Wi-Fi
Enables detection of hidden individuals and weapons in vehicles and sealed environments from human or drone-operated devices.
Click to join the public Inturai Telegram Channel https://t.me/inturai
VANCOUVER, BC, June 11, 2025 /CNW/ - P2P Group Ltd. (CSE: PPB) (FSE: 3QG) (US: PPBGF) is pleased to announce a major improvement in its wireless sensing platform, achieving heart rate and breathing detection at distances of up to 8 metres—more than doubling its prior range.
This enhancement strengthens both the SafeWave and StealthWave systems and significantly increases addressable market applications:
Border Security and Customs – Identifying concealed individuals in transport vehicles and closed compartments
National Defence and Tactical Teams – Gathering biometric intelligence without line of sight
Aged Care and Remote Health – Enabling unobtrusive, low-cost, and full room monitoring with no cameras, wearables, or privacy trade-offs
"Expanding the range to 8 metres without adding complexity is a very meaningful leap," said Ed Clarke, CEO of P2P Group. "This capability pushes us into new operational zones where traditional solutions simply can't go."
The Company is advancing IP protection, commercial rollout plans, and customer notifications. Updates will follow as deployment progresses.
About P2P Group
P2P Group is advancing intelligent environments through its proprietary Inturai AI signal sensing technology, transforming sectors including healthcare, defence, policing, emergency services, drones, smart homes, and industrial systems. By leveraging standard Wi-Fi and radio signals, Inturai delivers next-generation spatial intelligence without the need for invasive or specialist hardware. This breakthrough enables safer, smarter spaces across a range of high-impact use cases. To learn more, visit www.p2p-group.com.
This document contains certain forward-looking statements that are based on assumptions as of the date of this news release. Forward-looking statements are frequently characterised by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. All such forward-looking statements involve substantial known and unknown risks and uncertainties, certain of which are beyond the Company's control. The reader is cautioned that the assumptions used in the preparation of the forward-looking statements may prove to be incorrect and the actual results, performance or achievements could differ materially from those expressed in, or implied by, these forward-looking statements. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do, what benefits, including the amount of proceeds, the Company will derive therefrom. Readers are cautioned that the foregoing list of factors is not exhaustive. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/p2p-group-increases-biometric-detection-range-by-166transforming-security-defence-and-aged-care-302478448.html
SOURCE P2P Group Limited
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/June2025/11/c0687.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
9 hours ago
- Associated Press
Lobe Sciences Announces the Closing of the Previously Announced Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ('Lobe Sciences' or the 'Company') (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, announces the closing of the non-brokered private placement (the 'Offering') of up to 8,535,625 common share of the Company (each, a 'Share') at a price of $0.04 per Share for gross proceeds of up to $341,425 CAD. This offering was previously announced on July 29th. Securities to be issued pursuant to the Offering will be subject to a statutory four-month and one day hold period. None of the securities sold under the Offering have been and will not be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. About Lobe Sciences Ltd. Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) is a growth-stage biopharmaceutical company developing advanced treatments for rare and neurologically underserved conditions. Through its wholly owned subsidiary, Altemia, Inc., and majority-owned Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented lipid-based delivery platform for the treatment of Sickle Cell Disease and a proprietary oral analog of psilocin-Conjugated Psilocin™-targeted for Chronic Cluster Headache and related disorders. The Company's mission is to improve patient outcomes through innovation and precision-driven science. For further information, please contact: Dr. Fred D. Sancilio, CEO Lobe Sciences Ltd. Investor and Media [email protected] Phone: +1 (949) 505-5623 Website: Neither the 'CSE' Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statement Regarding 'Forward-Looking' Information This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the expectation that the Company will receive all necessary approvals to complete the Offering; the expectation that the Company will complete the Offering on the terms disclosed; and the intended use of proceeds of the Offering are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as 'intends' or 'anticipates', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'should' or 'would' or occur. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company will receive all necessary approvals to complete the Offering; that the Company will complete the Offering on the terms and timing anticipated; and that the proceeds from the Offering will be used as anticipated. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company will not receive the necessary approvals to complete the Offering; that the Company will not complete the Offering on the terms disclosed, or at all; and that the Company will be unable to use the proceeds received from the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws. SOURCE: Lobe Sciences Ltd. press release
Yahoo
19 hours ago
- Yahoo
Canadian Securities Exchange Reports July 2025 Performance Figures
Toronto, Ontario--(Newsfile Corp. - August 14, 2025) - The Canadian Securities Exchange ("CSE" or "the Exchange") today announced market statistics for July 2025. July 2025 Operating Statistics Trading volume of CSE listed securities totaled 1.6 billion shares; Trading value of CSE listed securities was $621 million; CSE issuers completed 92 financings that raised an aggregate $595 million; and The CSE welcomed listings from two new companies, both fundamental changes of existing issuers. The total number of listed securities was 748 as at July 31, 2025. "July was an extremely active period for the Canadian Securities Exchange, with trading activity reaching the highest level of any single month since 2022," said Richard Carleton, CEO of the CSE. "In addition, the month of July featured three of the four largest financings completed to date on the Exchange this year, as Asante Gold Corporation raised $236.8 million, Vireo Growth Inc. raised US$153 million, and Draganfly Inc. raised US$25 million. We were pleased to see such strong trading and financing activity during the traditionally slower summer season." What's On at the CSE The CSE is excited to be sponsoring and participating in the 2025 Canadian Security Traders Association (CSTA) conference, taking place in Ottawa on August 20-22. The annual conference brings together a diverse group of financial market experts to discuss key topics impacting capital markets. Richard Carleton will be speaking on a "Market Place Roundtable" panel on August 21 with senior executives from other Canadian exchanges. They will discuss issues shaping the future of securities trading in Canada. The CSE team will be returning to Beaver Creak Resort in Colorado for the annual Precious Metals Summit Beaver Creak on September 9-12. The invitation-only conference features nearly 200 mining companies and a who's who of expert speakers in the sector. Several CSE-listed companies are participating in the conference, including Abitibi Metals Corp. (AMQ), Asante Gold Corporation (ASE), Blue Lagoon Resources Inc. (BLLG), Exploits Discovery Corp. (NFLD), Headwater Gold Inc. (HWG), Kuya Silver Corporation (KUYA), and Yukon Metals Corp. (YMC). The CSE will be in Halifax on September 16 for its latest Going Public and Raising Capital in Canada event. These seminars provide entrepreneurs and company founders with detailed information and strategies to successfully enter Canada's capital markets. The line-up of expert speakers for this event includes Scott Pritchard, the CSE's Senior Advisor of Listings Development for Quebec and Eastern Canada, and James Black, the CSE's Vice President of Listings Development. Phillip Shum, Director of Listings Development, will also be in attendance and available to speak with attendees. The event also features a networking reception. New Listings in July 2025 SuperQ Quantum Computing Inc. (QBTQ) – Fundamental ChangeLibra Energy Materials Inc. (LIBR) – Fundamental Change About the Canadian Securities Exchange: The Canadian Securities Exchange is a rapidly growing exchange invested in working with entrepreneurs, innovators and disruptors to access public capital markets in Canada. The Exchange's efficient operating model, advanced technology and competitive fee structure help its listed issuers of all sectors and sizes minimize their cost of capital and enhance global liquidity. Our client-centric approach and corresponding products and services ensure businesses have the support they need to confidently realize their vision. The CSE offers global investors access to an innovative collection of growing and mature companies. STAY CONNECTED WITH THE CSE ============================= Website: TV on YouTube: CSE's "The Exchange for Entrepreneurs™" Podcast: Linkedin: (Twitter): Facebook: Contact:Richard Carleton, CEO 416-367-7360 To view the source version of this press release, please visit
Yahoo
a day ago
- Yahoo
Avicanna Reports Q2 2025
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ('Avicanna' or 'Company') (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products is pleased to announce and report the results of Q2 2025. Management Commentary: 'Q2 marked another milestone in Avicanna's journey, fueled by advancements in our pipeline and deeper engagement with the Canadian medical community. In Canada, we delivered growth across multiple commercial channels, underscoring the strength of our proprietary, high-margin portfolio. Achieving positive adjusted EBITDA for the first half of 2025 reflects the financial discipline and operational focus that continue to drive our performance. These results reinforce our ability to execute our strategy and position us for both domestic and international scale-up' stated Aras Azadian, CEO at Avicanna. Q2 2025 Financial Highlights: Revenue: The Company generated revenue of $6.16 million and $12.48 million for the three- and six-month periods ended June 30, 2025, representing a 1% increase and a 1% decrease, respectively, compared to the corresponding periods in 2024. Gross Profit and Margin: Gross profit for the second quarter was $3.13 million, with a six-month total of $6.73 million, translating to gross margins of 51% and 54%, respectively—up from 47% in the prior-year periods. This improvement was primarily driven by increased service and licensing revenue from international markets. Adjusted EBITDA: For the second quarter, the Company reported an adjusted EBITDA loss of $0.25 million and an adjusted EBITDA gain of $0.18 million for the six-month period. This marks a notable improvement from the same periods in 2024, when adjusted EBITDA losses were $0.44 million and $0.42 million, respectively. The improvement reflects both reduced operating expenses and enhanced gross margins. Other Q2 2025 Corporate Highlights: Canadian commercial advancements: The Company completed the second quarter with 50 commercial SKUs and 147 commercial listings representing a 19% increase in total SKUs and a 9% growth in total listings from Q1 2025. The Company sold 50,789 units during the second quarter, a 21% increase against the comparable period in 2024. Avicanna Announced Sponsorship of Pilot Phase II Clinical Study on Osteoarthritis Pain: The multicenter, blinded, randomized placebo-controlled investigator-initiated study is led by Dr. Hance Clarke and conducted at University Health Network. The study is to analyze effectiveness of Avicanna's proprietary oral cannabis extracts for osteoarthritic pain and is Avicanna's first placebo controlled, blinded randomized multicenter trial ('RCT'). The study is funded by a Canadian Institutes of Health Research grant and sponsored by Avicanna, which is providing its proprietary CBD and THC capsules produced under Good Manufacturing Practices for the trial. Symposium on Cannabinoid-based Medicine in June 2025: The Symposium, which was held at the MaRS Discovery District in Toronto, brought key opinion leaders and health care providers to explore cannabinoid-based R&D, medicine, and clinical adoption. The Symposium, which was limited to health care practitioners and researchers, covered a range of topics including emerging evidence and practical clinical applications of cannabinoid-based medicine and featured key opinion leaders, clinicians, researchers, and scientists from various academic, research and clinical organizations and hospitals and industry. Avicanna announced US Patent and Trademark Office issuance of new patent covering topical cannabinoid compositions for clear skin: The USPTO issued patent, No. US 12,343,315 B2, covering a topical gel formulation comprised of cannabinoids in combination with other agents in reference to its potential for treating and preventing skin diseases and conditions including, but not limited to, acne, wrinkles, rosacea and erythema. About Avicanna: Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars. Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform ( is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company's majority owned subsidiary Santa Marta Golden Hemp SAS ('SMGH') is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company's international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company's supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally. SOURCE Avicanna Inc. Stay Connected For more information about Avicanna, visit our website or contact Ivana Maric by email at info@ Cautionary Note Regarding Forward-Looking Information and Statements This news release contains 'forward-looking information' within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, 'may', 'would', 'could', 'will', 'likely', 'expect', 'anticipate', 'believe', 'intend', 'plan', 'forecast', 'project', 'estimate', 'outlook' and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 11, 2025, filed with the Canadian securities regulators and available under the Company's profile on SEDAR+ at The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
